Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC)

M Nocera; E Baudin; G Pellegriti; A F Cailleux; C Mechelany-Corone; M Schlumberger

doi:10.1054/bjoc.2000.1314

Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC)

Br J Cancer. 2000 Sep;83(6):715-8. doi: 10.1054/bjoc.2000.1314.

Authors

M Nocera¹, E Baudin, G Pellegriti, A F Cailleux, C Mechelany-Corone, M Schlumberger

Affiliation

¹ Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institute Gustave-Roussy, Villejuif Cedex, 94805, France.

Abstract

Combinations of doxorubicin and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 10 long-term stabilizations were observed. No unexpected toxicity occurred.

Publication types

Clinical Trial
Multicenter Study

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Medullary / drug therapy*
Carcinoma, Medullary / pathology
Dacarbazine / administration & dosage
Doxorubicin / administration & dosage
Drug Administration Schedule
Female
Fluorouracil / administration & dosage
Humans
Male
Middle Aged
Streptozocin / administration & dosage
Thyroid Neoplasms / drug therapy*
Thyroid Neoplasms / pathology
Treatment Outcome

Substances

Streptozocin
Dacarbazine
Doxorubicin
Fluorouracil